Opinion Paper

The role of rilpivirine in Southern Africa

Michelle A. Moorhouse, Karen Cohen
Southern African Journal of HIV Medicine | Vol 20, No 1 | a825 | DOI: https://doi.org/10.4102/sajhivmed.v20i1.825 | © 2019 Michelle A. Moorhouse, Karen Cohen | This work is licensed under CC Attribution 4.0
Submitted: 22 December 2017 | Published: 29 May 2019

About the author(s)

Michelle A. Moorhouse, Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa
Karen Cohen, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa


Share this article

Bookmark and Share

Abstract

Rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is included as an option in first-line antiretroviral therapy (ART) for antiretroviral-naïve individuals in treatment guidelines in high-income countries, including the United States and many European countries. Rilpivirine is available in a single-tablet fixed-dose combination, has a favourable tolerability profile and is of relatively low cost. However, rilpivirine has reduced efficacy in patients commencing ART at high viral loads. Therefore, baseline viral load testing is required before commencing rilpivirine, and it is not recommended for patients commencing therapy with a viral load greater than 100 000 copies/mL. Rilpivirine is not included in the treatment regimens recommended by the World Health Organization (WHO), which form the basis of treatment guidelines in many lower- and middle-income countries. Some patients commencing standard first-line regimens experience treatment-limiting toxicity. A low-cost rilpivirine-containing fixed-dose combination would potentially be a useful addition to treatment options available in South Africa and other countries in the region, for patients who do not tolerate standard first-line ART. In this article, we explore the utility of rilpivirine as an option in ART in South Africa and the region in the context of current public-sector regimens. We consider what role rilpivirine might play if first-line therapy moves to a dolutegravir-based regimen, as has already happened in some lower- and middle-income countries, including Botswana, Kenya and Brazil. Finally, we describe emerging evidence for rilpivirine in the prevention of HIV transmission.

Keywords

HIV; Rilpivirine; Antiretrovirals; Non-nucleoside reverse transcriptase inhibitor; Southern Africa

Metrics

Total abstract views: 352
Total article views: 262


Crossref Citations

No related citations found.